Fresenius finds demand for its paper in rude health
German healthcare company Fresenius this week opted to issue a €500m no-grow seven year trade following a roadshow, a choice which rewarded it with an order book that was more than five times subscribed.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: